{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:45:08Z","timestamp":1791499508349,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011221","name":"School of Medicine, University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>The objective of this systematic review is to examine the relationship between opioid use disorder (OUD) and its related biomarkers, as well as the effects of pharmacotherapy for OUD on biomarkers. The eligibility criteria are the inclusion of human population studies focusing on biomarkers, including the immune system, related to OUD or opioid-related disorders. English, peer reviewed, original research, case studies or case series, and clinical trials were included in this review. Papers were excluded if they met one or more of the following criteria: animal studies, review articles, studies focusing only on OUD or opioid-related disorders without mention of potential biomarkers, studies focusing only on biomarkers and\/or the immune system without relating to OUD or opioid-related disorders, and studies that focused on other substance use disorders other than OUD specifically. A PubMed, PsycINFO, and Cochrane databases search on August 25, 2020, yielded 101 results; only 14 articles met inclusion criteria that were included in this review. However, heterogeneity of study definitions and measurements should be noted. Various potential biomarkers indicated systemic, peripheral, and chronic inflammation in patients with OUD or opioid-related disorders. Medications, including buprenorphine and methadone, significantly decreased chronic inflammation in this population. Our results suggest that patients with OUD or opioid-related disorders have potential biomarkers that can be targeted to provide optimal treatment options for this population. A better understanding of potential biomarkers may assist to identify at-risk populations, monitor disease progression and treatment response, and develop therapeutic strategies for OUD.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold>This review has been registered in PROSPERO (CRD42020202014).<\/jats:p>","DOI":"10.3389\/fpsyt.2021.708283","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T05:49:52Z","timestamp":1628660992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A Systematic Review of Opioid Use Disorder and Related Biomarkers"],"prefix":"10.3389","volume":"12","author":[{"given":"Bianca M.","family":"Bryant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1186\/s12913-019-4751-4","article-title":"Opioid use disorder and treatment: challenges and opportunities","volume":"19","author":"Hoffman","year":"2019","journal-title":"BMC Health Serv Res."},{"key":"B2","article-title":"Reports of the Surgeon General","volume-title":"Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health","year":"2016"},{"key":"B3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11904-019-00463-4","article-title":"The opioid epidemic: impact on inflammation and cardiovascular disease risk in HIV","volume":"16","author":"Hileman","year":"2019","journal-title":"Curr HIV\/AIDS Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.3389\/fimmu.2019.02445","article-title":"The effects of opioids on HIV neuropathogenesis","volume":"10","author":"Murphy","year":"2019","journal-title":"Front Immunol."},{"key":"B5","first-page":"5","article-title":"Opioid system modulates the immune function: a review","volume":"1","author":"Liang","year":"2016","journal-title":"Transl Perioper Pain Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.4049\/jimmunol.0802763","article-title":"Mechanisms of opioid-mediated inhibition of human T cell receptor signaling","volume":"183","author":"B\u00f6rner","year":"2009","journal-title":"J Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11481-009-9145-7","article-title":"Inducible expression of functional mu opioid receptors in murine dendritic cells","volume":"4","author":"Li","year":"2009","journal-title":"J Neuroimmune Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11481-005-9009-8","article-title":"Modulation of immune function by morphine: implications for susceptibility to infection","volume":"1","author":"Roy","year":"2006","journal-title":"J Neuroimmune Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jneuroim.2005.11.009","article-title":"Suppression of natural killer cell activity by morphine is mediated by the nucleus accumbens shell","volume":"173","author":"Saurer","year":"2006","journal-title":"J Neuroimmunol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4049\/jimmunol.123.3.1068","article-title":"Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes","volume":"123","author":"Wybran","year":"1979","journal-title":"J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11481-006-9026-2","article-title":"Opioid receptors and signaling on cells from the immune system","volume":"1","author":"Bidlack","year":"2006","journal-title":"J Neuroimmune Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"107516","DOI":"10.1016\/j.drugalcdep.2019.06.018","article-title":"Correlation between interleukin-6 levels and methadone maintenance therapy outcomes","volume":"204","author":"Lu","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/npp.2016.198","article-title":"Psychoneuroimmunology of early-life stress: the hidden wounds of childhood trauma?","volume":"42","author":"Danese","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/oby.21143","article-title":"Childhood maltreatment increases the risk for visceral obesity","volume":"23","author":"Li","year":"2015","journal-title":"Obesity."},{"key":"B15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/7854","article-title":"Early-life adversity, systemic inflammation and comorbid physical and psychiatric illnesses of adult life","volume":"44","author":"Nettis","year":"2020","journal-title":"Curr Top Behav Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.psyneuen.2017.08.006","article-title":"More inflammation but less brain-derived neurotrophic factor in antisocial personality disorder","volume":"85","author":"Wang","year":"2017","journal-title":"Psychoneuroendocrinology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"107638","DOI":"10.1016\/j.drugalcdep.2019.107638","article-title":"Evaluation of dynorphin and kappa-opioid receptor level in the human blood lymphocytes and plasma: possible role as a biomarker in severe opioid use disorder","volume":"205","author":"Shahkarami","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"B18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/15321819.2018.1460272","article-title":"Complete blood count alterations due to the opioid use: what about the lymphocyte-related ratios, especially in monocyte to lymphocyte ratio and platelet to lymphocyte ratio?","volume":"39","author":"Orum","year":"2018","journal-title":"J Immunoassay Immunochem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2036145","DOI":"10.1155\/2018\/2036145","article-title":"Evaluation of immunomodulatory and hematologic cell outcome in heroin\/opioid addicts","volume":"2018","author":"Guzel","year":"2018","journal-title":"J Addict."},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000503880","article-title":"Neuro-Immuno-endocrine interactions in early life stress and heroin withdrawal timeline","volume":"26","author":"Moeini","year":"2020","journal-title":"Eur Addict Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s13365-012-0118-x","article-title":"Impact of opiate addiction on neuroinflammation in HIV","volume":"18","author":"Byrd","year":"2012","journal-title":"J Neurovirol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"107511","DOI":"10.1016\/j.drugalcdep.2019.06.014","article-title":"Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment","volume":"204","author":"McGinnis","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/JLB.3CE0418-172R","article-title":"Buprenorphine: therapeutic potential beyond substance abuse","volume":"104","author":"Velasquez","year":"2018","journal-title":"J Leukoc Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/JLB.3HI0118-015R","article-title":"Frontline science: buprenorphine decreases CCL2-mediated migration of CD14 (+) CD16 (+) monocytes","volume":"104","author":"Jaureguiberry-Bravo","year":"2018","journal-title":"J Leukoc Biol."},{"key":"B25","first-page":"46","article-title":"Opioid use disorder induces oxidative stress and inflammation: the attenuating effect of methadone maintenance treatment","volume":"13","author":"Salarian","year":"2018","journal-title":"Iran J Psychiatry."},{"key":"B26","first-page":"e00769","article-title":"Quantifying absolute glutamate concentrations in nucleus accumbens of prescription opioid addicts by using (1)H MR","volume-title":"Brain Behav","author":"Liu","year":"2017"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s11606-020-06001-y","article-title":"Perioperative serum 25-hydroxyvitamin D levels as a predictor of postoperative opioid use and opioid use disorder: a cohort study","volume":"35","author":"Kim","year":"2020","journal-title":"J Gen Intern Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"eabe4577","DOI":"10.1126\/sciadv.abe4577","article-title":"Vitamin D deficiency exacerbates UV\/endorphin and opioid addiction","volume":"7","author":"Kem\u00e9ny","year":"2021","journal-title":"Sci Adv"},{"key":"B29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fncel.2018.00458","article-title":"The interleukin-10 family of cytokines and their role in the CNS","volume":"12","author":"Burmeister","year":"2018","journal-title":"Front Cell Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","article-title":"Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit Rev Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugalcdep.2018.10.002","article-title":"A hidden aspect of the U","volume":"193","author":"Huhn","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drugalcdep.2014.12.019","article-title":"Mortality among older adults with opioid use disorders in the veteran's health administration, 2000-2011","volume":"147","author":"Larney","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1542\/peds.2019-2056C","article-title":"Management of opioid misuse and opioid use disorders among youth","volume":"145","author":"Robinson","year":"2020","journal-title":"Pediatrics."},{"key":"B35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/jamapediatrics.2017.1269","article-title":"Closing the medication-assisted treatment gap for youth with opioid use disorder","volume":"171","author":"Saloner","year":"2017","journal-title":"JAMA Pediatr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.36076\/ppj.2018.1.e1","article-title":"Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures","volume":"21","author":"Jonan","year":"2018","journal-title":"Pain Physician."},{"key":"B37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.708283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T03:07:33Z","timestamp":1673060853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.708283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":37,"alternative-id":["10.3389\/fpsyt.2021.708283"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.708283","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"article-number":"708283"}}